托珠单抗阻断白细胞介素-6受体治疗89例COVID-19肺炎住院患者的临床和实验室反应

Q1 Medicine Pathogens and Immunity Pub Date : 2020-10-02 eCollection Date: 2020-01-01 DOI:10.20411/pai.v5i1.392
Daria S Fomina, Mar'yana A Lysenko, Irina P Beloglazova, Zinaida Yu Mutovina, Nataliya G Poteshkina, Inna V Samsonova, Tat'yana S Kruglova, Anton A Chernov, Alexander V Karaulov
{"title":"托珠单抗阻断白细胞介素-6受体治疗89例COVID-19肺炎住院患者的临床和实验室反应","authors":"Daria S Fomina,&nbsp;Mar'yana A Lysenko,&nbsp;Irina P Beloglazova,&nbsp;Zinaida Yu Mutovina,&nbsp;Nataliya G Poteshkina,&nbsp;Inna V Samsonova,&nbsp;Tat'yana S Kruglova,&nbsp;Anton A Chernov,&nbsp;Alexander V Karaulov","doi":"10.20411/pai.v5i1.392","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pandemic COVID-19 pneumonia due to SARS-2 is an important cause of morbidity and mortality. Emerging evidence links poor outcomes to an inflammatory cytokine storm.</p><p><strong>Methods: </strong>We treated 89 hospitalized patients with COVID-19 pneumonia and heightened systemic inflammation (elevated serum C reactive protein and interleukin-6 levels) with an infusion of tocilizumab (TCZ), a human monoclonal IgG1 antibody to the interleukin-6 receptor.</p><p><strong>Results: </strong>Clinical and laboratory evidence of improvement was evident when baseline and 1-2-day post-infusion indices were compared. Among the 72 patients receiving supplemental oxygen without mechanical ventilation, severity of condition on the NEWS2 scale scores fell from 5 to 2 (<i>P<</i>0.001), C reactive protein levels fell from 95 to 14 mg/L (<i>P<</i>0.001), and lymphocyte counts rose from 900 to 1000/uL (<i>P</i>=0.036). Sixty-three of 72 patients were discharged from the hospital, one patient died, and eight patients remained in the hospital at the time of this writing. Among the 17 patients receiving mechanical ventilation, despite a rapid decrease in CRP levels from 89 to 35 mg/L (<i>P</i>=0.014) and early improvements in NEWS2 scores in 10 of 17 patients, 10 patients ultimately died and the other seven remain in the hospital at the time of this writing. Overall, mortality was only seen in patients who had markedly elevated CRP levels (>30 mg/L) and low lymphocyte counts (<1000/uL) before TCZ administration.</p><p><strong>Conclusions: </strong>Inflammation and lymphocytopenia are linked to mortality in COVID-19. Inhibition of IL-6 activity by administration of tocilizumab, an anti-IL-6 receptor antibody, is associated with rapid improvement in both CRP and lymphocyte counts and in clinical indices. Controlled clinical trials are needed to confirm the utility of IL-6 blockade in this setting. Additional interventions will be needed for patients requiring mechanical ventilation.</p>","PeriodicalId":36419,"journal":{"name":"Pathogens and Immunity","volume":" ","pages":"327-341"},"PeriodicalIF":0.0000,"publicationDate":"2020-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556411/pdf/","citationCount":"24","resultStr":"{\"title\":\"Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia.\",\"authors\":\"Daria S Fomina,&nbsp;Mar'yana A Lysenko,&nbsp;Irina P Beloglazova,&nbsp;Zinaida Yu Mutovina,&nbsp;Nataliya G Poteshkina,&nbsp;Inna V Samsonova,&nbsp;Tat'yana S Kruglova,&nbsp;Anton A Chernov,&nbsp;Alexander V Karaulov\",\"doi\":\"10.20411/pai.v5i1.392\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Pandemic COVID-19 pneumonia due to SARS-2 is an important cause of morbidity and mortality. Emerging evidence links poor outcomes to an inflammatory cytokine storm.</p><p><strong>Methods: </strong>We treated 89 hospitalized patients with COVID-19 pneumonia and heightened systemic inflammation (elevated serum C reactive protein and interleukin-6 levels) with an infusion of tocilizumab (TCZ), a human monoclonal IgG1 antibody to the interleukin-6 receptor.</p><p><strong>Results: </strong>Clinical and laboratory evidence of improvement was evident when baseline and 1-2-day post-infusion indices were compared. Among the 72 patients receiving supplemental oxygen without mechanical ventilation, severity of condition on the NEWS2 scale scores fell from 5 to 2 (<i>P<</i>0.001), C reactive protein levels fell from 95 to 14 mg/L (<i>P<</i>0.001), and lymphocyte counts rose from 900 to 1000/uL (<i>P</i>=0.036). Sixty-three of 72 patients were discharged from the hospital, one patient died, and eight patients remained in the hospital at the time of this writing. Among the 17 patients receiving mechanical ventilation, despite a rapid decrease in CRP levels from 89 to 35 mg/L (<i>P</i>=0.014) and early improvements in NEWS2 scores in 10 of 17 patients, 10 patients ultimately died and the other seven remain in the hospital at the time of this writing. Overall, mortality was only seen in patients who had markedly elevated CRP levels (>30 mg/L) and low lymphocyte counts (<1000/uL) before TCZ administration.</p><p><strong>Conclusions: </strong>Inflammation and lymphocytopenia are linked to mortality in COVID-19. Inhibition of IL-6 activity by administration of tocilizumab, an anti-IL-6 receptor antibody, is associated with rapid improvement in both CRP and lymphocyte counts and in clinical indices. Controlled clinical trials are needed to confirm the utility of IL-6 blockade in this setting. Additional interventions will be needed for patients requiring mechanical ventilation.</p>\",\"PeriodicalId\":36419,\"journal\":{\"name\":\"Pathogens and Immunity\",\"volume\":\" \",\"pages\":\"327-341\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556411/pdf/\",\"citationCount\":\"24\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pathogens and Immunity\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20411/pai.v5i1.392\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathogens and Immunity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20411/pai.v5i1.392","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 24

摘要

背景:由SARS-2引起的COVID-19大流行肺炎是发病和死亡的重要原因。新出现的证据表明,不良结果与炎症细胞因子风暴有关。方法:我们通过输注tocilizumab (TCZ)治疗89例住院的COVID-19肺炎并全身炎症升高(血清C反应蛋白和白细胞介素-6水平升高)的患者,TCZ是一种针对白细胞介素-6受体的人单克隆IgG1抗体。结果:当基线和输注后1-2天的指标进行比较时,临床和实验室证据明显改善。72例接受无机械通气补充氧治疗的患者,病情严重程度NEWS2评分从5降至2 (P0.001), C反应蛋白水平从95降至14 mg/L (P0.001),淋巴细胞计数从900上升至1000/uL (P=0.036)。72例患者中63例出院,1例死亡,8例患者在撰写本文时仍住院。在接受机械通气的17例患者中,尽管CRP水平从89迅速下降到35 mg/L (P=0.014), 17例患者中有10例NEWS2评分早期改善,但10例患者最终死亡,其他7例患者在撰写本文时仍在医院。总体而言,只有CRP水平显著升高(>30 mg/L)和淋巴细胞计数低的患者才会出现死亡率(结论:炎症和淋巴细胞减少与COVID-19的死亡率有关)。通过给予抗IL-6受体抗体tocilizumab抑制IL-6活性,与CRP和淋巴细胞计数以及临床指标的快速改善有关。在这种情况下,需要对照临床试验来证实IL-6阻断的效用。需要机械通气的患者需要额外的干预措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia.

Background: Pandemic COVID-19 pneumonia due to SARS-2 is an important cause of morbidity and mortality. Emerging evidence links poor outcomes to an inflammatory cytokine storm.

Methods: We treated 89 hospitalized patients with COVID-19 pneumonia and heightened systemic inflammation (elevated serum C reactive protein and interleukin-6 levels) with an infusion of tocilizumab (TCZ), a human monoclonal IgG1 antibody to the interleukin-6 receptor.

Results: Clinical and laboratory evidence of improvement was evident when baseline and 1-2-day post-infusion indices were compared. Among the 72 patients receiving supplemental oxygen without mechanical ventilation, severity of condition on the NEWS2 scale scores fell from 5 to 2 (P<0.001), C reactive protein levels fell from 95 to 14 mg/L (P<0.001), and lymphocyte counts rose from 900 to 1000/uL (P=0.036). Sixty-three of 72 patients were discharged from the hospital, one patient died, and eight patients remained in the hospital at the time of this writing. Among the 17 patients receiving mechanical ventilation, despite a rapid decrease in CRP levels from 89 to 35 mg/L (P=0.014) and early improvements in NEWS2 scores in 10 of 17 patients, 10 patients ultimately died and the other seven remain in the hospital at the time of this writing. Overall, mortality was only seen in patients who had markedly elevated CRP levels (>30 mg/L) and low lymphocyte counts (<1000/uL) before TCZ administration.

Conclusions: Inflammation and lymphocytopenia are linked to mortality in COVID-19. Inhibition of IL-6 activity by administration of tocilizumab, an anti-IL-6 receptor antibody, is associated with rapid improvement in both CRP and lymphocyte counts and in clinical indices. Controlled clinical trials are needed to confirm the utility of IL-6 blockade in this setting. Additional interventions will be needed for patients requiring mechanical ventilation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pathogens and Immunity
Pathogens and Immunity Medicine-Infectious Diseases
CiteScore
10.60
自引率
0.00%
发文量
16
审稿时长
10 weeks
期刊最新文献
Historical Highlight: The Luria-Delbrück Fluctuation Test - A Study of the Nature of Bacterial Mutations Conferring Resistance to Infection by Bacteriophage. Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP3.3 From Approved Monoclonal Antibodies. Jonathan Yewdell Discusses Viral Immunology, Vaccine Development, Navigating a Scientific Career, and Offers Perspectives on Transforming Scientific Publishing and Research Education. Effect of Ceftaroline, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam on Establishment of Colonization by Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice. People Living With HIV Have More Intact HIV DNA in Circulating CD4+ T Cells if They Have History of Pulmonary Tuberculosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1